idarubicin and mesna
idarubicin has been researched along with mesna in 6 studies
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Albera, C; Bèguelin, R; Cacchione, R; Campestri, R; Dragosky, M; Dupont, J; Fernández, J; Garay, G; Nicastro, M; Noviello, V; Nucifora, E; Riveros, D; Schnidrig, P; Triguboff, E | 1 |
| Alcorn, MJ; Cook, G; Farrell, E; Franklin, IM; Marinaki, P; Pearson, C; Sharp, RA; Tansey, PJ | 1 |
| Avramis, V; Douglas, JG; Felgenhauer, J; Geyer, JR; Hawkins, DS; Holcenberg, J; Loken, MR; Meshinchi, S; Park, JR; Thomson, B | 1 |
| Alcalde-Ruiz, E; Catala-Mora, J; Chantada, GL; Croxatto, JO; Dabezies, AP; de Dávila, MTG; Dufort, G; Fandiño, AC; Kopp, K; López, JP; Ossandon, D; Parareda-Salles, A; Pérez, V; Ravindranath, Y; Reaman, G; Rey, G; Sampor, C; Suñol, M; Urbieta, M; Zelter, M | 1 |
Reviews
1 review(s) available for idarubicin and mesna
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Trials
3 trial(s) available for idarubicin and mesna
| Article | Year |
|---|---|
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Recurrence; Salvage Therapy | 1997 |
Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Male; Mesna; Middle Aged; Multiple Myeloma; Remission Induction | 1997 |
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacteremia; Bone Marrow Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Ifosfamide; Infant; Infusions, Intravenous; Leucovorin; Male; Mesna; Methotrexate; Mouth Mucosa; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stomatitis; Thioguanine; Treatment Outcome; Vincristine | 2004 |
Other Studies
2 other study(ies) available for idarubicin and mesna
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Treatment of Nonmetastatic Unilateral Retinoblastoma in Children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Eye Enucleation; Female; Humans; Hydrophthalmos; Idarubicin; Infant; Male; Mesna; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Retinal Neoplasms; Retinoblastoma; Survival Rate; Vincristine | 2018 |